User login
Key clinical point: In patients with psoriatic arthritis (PsA), early onset psoriasis (EOP) was linked to dactylitis and more frequent use of anti-interleukin 17 (anti-IL17) drugs, whereas late onset psoriasis (LOP) was associated with a higher use of nonsteroidal anti-inflammatory drugs (NSAID) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD).
Major finding: Patients in the EOP vs LOP group had a 9 times higher probability of dactylitis (odds ratio [OR] 9.64; P < .001) and reported a higher use of anti-IL17 drugs (26.8% vs 13.5%; P = .039); meanwhile, in the LOP vs EOP group, the use of NSAID (29.7% vs 12.2%; P = .016) and csDMARD (21.6% vs 7.3%; P < .01) was more frequent.
Study details: The data come from a cross-sectional analysis of a longitudinal cohort including 160 patients with PsA, of which 84 had EOP (0-40 years) and 76 patients had LOP (>40 years).
Disclosures: This study did not receive any funding or sponsorship. The authors declared no conflicts of interest.
Source: Scriffignano S et al. Dactylitis and early onset psoriasis in psoriatic arthritis: Are they markers of disease severity? A clinical study. Rheumatol Ther. 2022 (Jun 17). Doi: 10.1007/s40744-022-00468-3
Key clinical point: In patients with psoriatic arthritis (PsA), early onset psoriasis (EOP) was linked to dactylitis and more frequent use of anti-interleukin 17 (anti-IL17) drugs, whereas late onset psoriasis (LOP) was associated with a higher use of nonsteroidal anti-inflammatory drugs (NSAID) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD).
Major finding: Patients in the EOP vs LOP group had a 9 times higher probability of dactylitis (odds ratio [OR] 9.64; P < .001) and reported a higher use of anti-IL17 drugs (26.8% vs 13.5%; P = .039); meanwhile, in the LOP vs EOP group, the use of NSAID (29.7% vs 12.2%; P = .016) and csDMARD (21.6% vs 7.3%; P < .01) was more frequent.
Study details: The data come from a cross-sectional analysis of a longitudinal cohort including 160 patients with PsA, of which 84 had EOP (0-40 years) and 76 patients had LOP (>40 years).
Disclosures: This study did not receive any funding or sponsorship. The authors declared no conflicts of interest.
Source: Scriffignano S et al. Dactylitis and early onset psoriasis in psoriatic arthritis: Are they markers of disease severity? A clinical study. Rheumatol Ther. 2022 (Jun 17). Doi: 10.1007/s40744-022-00468-3
Key clinical point: In patients with psoriatic arthritis (PsA), early onset psoriasis (EOP) was linked to dactylitis and more frequent use of anti-interleukin 17 (anti-IL17) drugs, whereas late onset psoriasis (LOP) was associated with a higher use of nonsteroidal anti-inflammatory drugs (NSAID) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD).
Major finding: Patients in the EOP vs LOP group had a 9 times higher probability of dactylitis (odds ratio [OR] 9.64; P < .001) and reported a higher use of anti-IL17 drugs (26.8% vs 13.5%; P = .039); meanwhile, in the LOP vs EOP group, the use of NSAID (29.7% vs 12.2%; P = .016) and csDMARD (21.6% vs 7.3%; P < .01) was more frequent.
Study details: The data come from a cross-sectional analysis of a longitudinal cohort including 160 patients with PsA, of which 84 had EOP (0-40 years) and 76 patients had LOP (>40 years).
Disclosures: This study did not receive any funding or sponsorship. The authors declared no conflicts of interest.
Source: Scriffignano S et al. Dactylitis and early onset psoriasis in psoriatic arthritis: Are they markers of disease severity? A clinical study. Rheumatol Ther. 2022 (Jun 17). Doi: 10.1007/s40744-022-00468-3